PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30543859-2 2019 We have evaluated the effects of intraperitoneal administration of pioglitazone, a peroxisome proliferator-activated receptor (PPAR) gamma agonist, on LB in mice tracheal transplant model. Pioglitazone 67-79 peroxisome proliferator activated receptor alpha Mus musculus 83-125 33983968-16 2021 The GRT-pioglitazone-atorvastatin combination therapy downregulated Apoa1 (p = 0.006), whilst upregulating Fasn (p = 0.005), Pparalpha (p = 0.041), and Srebp1 (p = 0.03). Pioglitazone 8-20 peroxisome proliferator activated receptor alpha Mus musculus 125-134 33192313-12 2020 These data support our previous results demonstrating significant protection of auditory HCs in the OC explants exposed to pioglitazone and other PPAR-targeted agents. Pioglitazone 123-135 peroxisome proliferator activated receptor alpha Mus musculus 146-150 30957417-9 2019 Furthermore, we confirmed that PPARalpha and PPARgamma activation by WY14643 and pioglitazone, respectively, alleviated oleate-induced accumulation of total cholesterol, esterified cholesterol and neutral lipids by accelerating ABC transporter A1/G1-mediated cholesterol efflux. Pioglitazone 81-93 peroxisome proliferator activated receptor alpha Mus musculus 31-40 30543859-2 2019 We have evaluated the effects of intraperitoneal administration of pioglitazone, a peroxisome proliferator-activated receptor (PPAR) gamma agonist, on LB in mice tracheal transplant model. Pioglitazone 67-79 peroxisome proliferator activated receptor alpha Mus musculus 127-131 28831172-7 2017 Knockdown PPARalpha/PPARgamma in AML12 cells significantly and proportionally reduced the expressions of ATGL, CPT-1A and LC3II, which was induced by pioglitazone. Pioglitazone 150-162 peroxisome proliferator activated receptor alpha Mus musculus 10-19 28831172-9 2017 Our results demonstrated that pioglitazone attenuating the hepatic steatosis may be mediated by enhancing cytosolic lipolysis, beta-oxidation and autophagy in a PPARalpha and PPARgamma dependent manner. Pioglitazone 30-42 peroxisome proliferator activated receptor alpha Mus musculus 161-170 24838579-2 2015 In the past, specific peroxisome proliferator-activated receptor (PPAR)gamma-agonists, such as pioglitazone, have been tested with limited success to improve AD pathology. Pioglitazone 95-107 peroxisome proliferator activated receptor alpha Mus musculus 66-70 23362873-6 2013 The treatment of mice skin with the PPARgamma and PPARalpha agonists, pioglitazone and WY14643, was associated with significant increase in photons emission reaching maximal signalling at 6 h. We have performed dose response studies by testing a large range of pioglitazone and WY14643 concentrations on mouse skin. Pioglitazone 70-82 peroxisome proliferator activated receptor alpha Mus musculus 50-59 23362873-6 2013 The treatment of mice skin with the PPARgamma and PPARalpha agonists, pioglitazone and WY14643, was associated with significant increase in photons emission reaching maximal signalling at 6 h. We have performed dose response studies by testing a large range of pioglitazone and WY14643 concentrations on mouse skin. Pioglitazone 261-273 peroxisome proliferator activated receptor alpha Mus musculus 50-59 23362873-7 2013 The specificity of bioluminescence signal induced by pioglitazone and WY14643 was assessed using PPARgamma and PPARalpha antagonists, GW9662 and GW6471, respectively. Pioglitazone 53-65 peroxisome proliferator activated receptor alpha Mus musculus 111-120 21777645-2 2011 Peroxisome proliferator-activated receptor (PPAR) ligands are reported to activate the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, including pioglitazone, which belong to the thiazolidinedione (TZD). Pioglitazone 147-159 peroxisome proliferator activated receptor alpha Mus musculus 0-42 21777645-2 2011 Peroxisome proliferator-activated receptor (PPAR) ligands are reported to activate the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, including pioglitazone, which belong to the thiazolidinedione (TZD). Pioglitazone 147-159 peroxisome proliferator activated receptor alpha Mus musculus 44-48 20798360-0 2010 Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}. Pioglitazone 0-12 peroxisome proliferator activated receptor alpha Mus musculus 106-110 20185806-10 2010 MGL1(med)/CD11c(+) ATMPhis expressing elevated PGC-1alpha, PPAR-alpha, and Ym-1 transcripts were selectively enriched in eAT of obese mice fed pioglitazone for 6 days, confirming the M2 features of the MGL1(med)/CD11c(+) eATMPhi transcriptional profile and implicating PPAR activation in its elicitation. Pioglitazone 143-155 peroxisome proliferator activated receptor alpha Mus musculus 59-69 20185806-10 2010 MGL1(med)/CD11c(+) ATMPhis expressing elevated PGC-1alpha, PPAR-alpha, and Ym-1 transcripts were selectively enriched in eAT of obese mice fed pioglitazone for 6 days, confirming the M2 features of the MGL1(med)/CD11c(+) eATMPhi transcriptional profile and implicating PPAR activation in its elicitation. Pioglitazone 143-155 peroxisome proliferator activated receptor alpha Mus musculus 59-63 18755353-0 2008 The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice. Pioglitazone 61-73 peroxisome proliferator activated receptor alpha Mus musculus 102-150 18755353-1 2008 OBJECTIVES: Our aim was to investigate if the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone modulates inflammation through PPARalpha mechanisms. Pioglitazone 110-122 peroxisome proliferator activated receptor alpha Mus musculus 154-163 18755353-6 2008 Since both triglyceride-lowering and VCAM-1 repression characterize PPARalpha activation, we studied pioglitazone"s effects via PPARalpha. Pioglitazone 101-113 peroxisome proliferator activated receptor alpha Mus musculus 128-137 18755353-7 2008 METHODS: Pioglitazone effects on known PPARalpha responses--ligand binding domain activation and PPARalpha target gene expression--were tested in vitro and in vivo, including in wild-type and PPARalpha-deficient cells and mice, and compared with the effects of other PPARgamma (rosiglitazone) and PPARalpha (WY14643) agonists. Pioglitazone 9-21 peroxisome proliferator activated receptor alpha Mus musculus 39-48 18755353-7 2008 METHODS: Pioglitazone effects on known PPARalpha responses--ligand binding domain activation and PPARalpha target gene expression--were tested in vitro and in vivo, including in wild-type and PPARalpha-deficient cells and mice, and compared with the effects of other PPARgamma (rosiglitazone) and PPARalpha (WY14643) agonists. Pioglitazone 9-21 peroxisome proliferator activated receptor alpha Mus musculus 97-106 18755353-7 2008 METHODS: Pioglitazone effects on known PPARalpha responses--ligand binding domain activation and PPARalpha target gene expression--were tested in vitro and in vivo, including in wild-type and PPARalpha-deficient cells and mice, and compared with the effects of other PPARgamma (rosiglitazone) and PPARalpha (WY14643) agonists. Pioglitazone 9-21 peroxisome proliferator activated receptor alpha Mus musculus 97-106 18755353-7 2008 METHODS: Pioglitazone effects on known PPARalpha responses--ligand binding domain activation and PPARalpha target gene expression--were tested in vitro and in vivo, including in wild-type and PPARalpha-deficient cells and mice, and compared with the effects of other PPARgamma (rosiglitazone) and PPARalpha (WY14643) agonists. Pioglitazone 9-21 peroxisome proliferator activated receptor alpha Mus musculus 97-106 18755353-8 2008 RESULTS: Pioglitazone repressed endothelial TNFalpha-induced VCAM-1 messenger ribonucleic acid expression and promoter activity, and induced hepatic IkappaBalpha in a manner dependent on both pioglitazone exposure and PPARalpha expression. Pioglitazone 9-21 peroxisome proliferator activated receptor alpha Mus musculus 218-227 18755353-9 2008 Pioglitazone also activated the PPARalpha ligand binding domain and induced PPARalpha target gene expression, with in vitro effects that were most pronounced in endothelial cells. Pioglitazone 0-12 peroxisome proliferator activated receptor alpha Mus musculus 32-41 18755353-9 2008 Pioglitazone also activated the PPARalpha ligand binding domain and induced PPARalpha target gene expression, with in vitro effects that were most pronounced in endothelial cells. Pioglitazone 0-12 peroxisome proliferator activated receptor alpha Mus musculus 76-85 18755353-11 2008 CONCLUSIONS: Pioglitazone regulates inflammatory target genes in hepatic (IkappaBalpha) and endothelial (VCAM-1) settings in a PPARalpha-dependent manner. Pioglitazone 13-25 peroxisome proliferator activated receptor alpha Mus musculus 127-136 34736656-1 2022 Pioglitazone is a Peroxisome Proliferator-Activated Receptor (PPAR) agonist of the thiazolidinedione class of compounds with promising anticancer activity. Pioglitazone 0-12 peroxisome proliferator activated receptor alpha Mus musculus 18-60 34736656-1 2022 Pioglitazone is a Peroxisome Proliferator-Activated Receptor (PPAR) agonist of the thiazolidinedione class of compounds with promising anticancer activity. Pioglitazone 0-12 peroxisome proliferator activated receptor alpha Mus musculus 62-66